Financial Performance - Revenues reached ₹8,545 Cr, showing an 11% YoY growth[9] - EBITDA stood at ₹2,278 Cr with a margin of 26.7%[9] - Profit Before Tax (PBT) was ₹1,905 Cr, representing 22%[9] - Profit After Tax (PAT) amounted to ₹1,418 Cr, which is 17%[9] Segment Performance - Global Generics contributed ₹7,562 Cr, with a 10% YoY increase[13] - North America generated ₹3,412 Cr in revenue, up by 11% YoY[13] - India's revenue was ₹1,471 Cr, marking an 11% YoY growth[13] - Europe reported revenue of ₹1,274 Cr, a significant 142% YoY increase, including revenues from the acquired NRT business[13] - Pharmaceutical Services & Active Ingredients (PSAI) achieved ₹818 Cr in revenue, a 7% YoY increase[13] - Emerging Markets reached ₹1,404 Cr in revenue, showing an 18% YoY increase[13] Financial Position - Net Cash surplus at ₹2,922 Cr as of June 30, 2025[11, 22]